


## Nilotinib

**ALTERNATE NAME:** 4-methyl-*N*-[3-(4-methyl-1*H*-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3- [(4-pyridin-3-yl)pyrimidin-2-yl]amino]benzamide

**CATALOG #:** 1750-25, 100

**AMOUNT:** 25 mg, 100 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>28</sub>H<sub>22</sub>F<sub>3</sub>N<sub>7</sub>O

**MOLECULAR WEIGHT:** 529.52

**CAS NUMBER:** 641571-10-0

**APPEARANCE:** Off-white solid

**SOLUBILITY:** DMSO (50 mg/ml)

**PURITY:** ≥98% by HPLC

**STORAGE:** Store at -20 °C

**DESCRIPTION:** A potent, selective BCR-ABL inhibitor that fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib (Cat. No. 1625-100, 1000). Nilotinib is not only more potent than imatinib against wild-type BCR-ABL (IC<sub>50</sub> < 30 nM), but also significantly active against 32/33 imatinib-resistant BCR-ABL mutants.

**REFERENCE:** Weisberg, E., *et al.* (2006). *Br. J. Cancer* **94**, 1765-1769.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**FOR RESEARCH USE ONLY! Not to be used on humans.**

### RELATED PRODUCTS:

- Bosutinib (Cat. No. 1584-5, 25)
- Dasatinib (Cat. No. 1586-25, 100)
- Erlotinib, Hydrochloride (Cat. No. 1588-100, 1000)
- Gefitinib (Cat. No. 1589-5, 25)
- Imatinib Mesylate (Cat. No. 1625-100, 1000)
- Lapatinib Ditosylate (Cat. No. 1624-25, 100)
- Sorafenib (Cat. No. 1594-25, 100)
- Sunitinib Malate (Cat. No. 1611-100, 1000)